Classification and Personalized Prognosis in Myeloproliferative Neoplasms | Zendy

Jacob Grinfeld | Zendy; Jyoti Nangalia | Zendy; E. Joanna Baxter | Zendy; David C. Wedge | Zendy; Nicos Angelopoulos | Zendy; R. Cantrill | Zendy; Anna L. Godfrey | Zendy; Elli Papaemmanuil | Zendy; Gunes Gundem | Zendy; Cathy MacLean | Zendy; Julia Cook | Zendy; Laura O’Neil | Zendy; Sarah O’Meara | Zendy; Jon W. Teague | Zendy; Adam P. Butler | Zendy; Charlie E. Massie | Zendy; Nicholas Williams | Zendy; Francesca Nice | Zendy; Christen Lykkegaard Andersen | Zendy; Hans Carl Hasselbalch | Zendy; Paola Guglielmelli | Zendy; Mary Frances McMullin | Zendy; Alessandro M. Vannucchi | Zendy; Claire Harrison | Zendy; Moritz Gerstung | Zendy; Anthony R. Green | Zendy; Peter J. Campbell | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Classification and Personalized Prognosis in Myeloproliferative Neoplasms

Author(s) -

Jacob Grinfeld,

Jyoti Nangalia,

E. Joanna Baxter,

David C. Wedge,

Nicos Angelopoulos,

R. Cantrill,

Anna L. Godfrey,

Elli Papaemmanuil,

Gunes Gundem,

Cathy MacLean,

Julia Cook,

Laura O’Neil,

Sarah O’Meara,

Jon W. Teague,

Adam P. Butler,

Charlie E. Massie,

Nicholas Williams,

Francesca Nice,

Christen Lykkegaard Andersen,

Hans Carl Hasselbalch,

Paola Guglielmelli,

Mary Frances McMullin,

Alessandro M. Vannucchi,

Claire Harrison,

Moritz Gerstung,

Anthony R. Green,

Peter J. Campbell

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1716614

Subject(s) - essential thrombocythemia , polycythemia vera , myelofibrosis , medicine , myeloproliferative disorders , risk stratification , oncology , pathology , bone marrow

Myeloproliferative neoplasms, such as polycythemia vera, essential thrombocythemia, and myelofibrosis, are chronic hematologic cancers with varied progression rates. The genomic characterization of patients with myeloproliferative neoplasms offers the potential for personalized diagnosis, risk stratification, and treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research